The recent introduction of VEGF inhibitor therapies in cancer patients and its preeclampsia-like adverse effects, particularly hypertension and renal injury, have attracted much attention and made doubly sure that inhibiting the VEGF signal pathway is central to the pathophysiology in preeclampsia [41,42,43,44,45,46]. Here, VEGFA is linked to cancer.